Journal of public health (Oxford, England) · 2026
Increasing burden of multiple long-term conditions and mortality risk following COVID-19 diagnosis: a national cohort study of one million adults with cardiovascular disease in England.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chudasama Yogini V, Shabnam Sharmin, Khunti Kamlesh, Razieh Cameron, Gillies Clare L, Islam Nazrul, Yates Thomas, Banerjee Amitava, Conrad Nathalie, Denaxas Spiros, Lawson Claire, Zaccardi Francesco
Аннотация
BACKGROUND: Individuals with cardiovascular disease (CVD) experienced high mortality during coronavirus disease 2019 (COVID-19), yet most live with multiple long-term conditions (MLTCs). We examined the association between MLTCs burden and mortality following COVID-19 among people with CVD.
METHODS: In this population-based cohort study, linked national electronic health records from England were analysed. Adults aged ≥18 years with CVD and a positive COVID-19 test between 31 January 2020 and 31 October 2022 were included. MLTCs burden was defined as the number of additional long-term conditions beyond CVD (0, 1, 2, or ≥3). One-year mortality was assessed using adjusted flexible parametric Royston-Parmar models.
RESULTS: In 1 081 695 individuals with CVD and COVID-19, 89.7% had at least one long-term condition (LTC) and 67.9% had two or more. Increasing MLTC burden showed a dose-response association with mortality. Compared to individuals without additional LTCs, mortality risk was doubled for those with one LTC (adjusted hazard ratio: 1.86, 95% CI: 1.76-1.96), tripled among those with two LTCs (3.00, 2.85-3.16), and five-fold higher in those with ≥3 LTCs (5.00, 4.75-5.27). Associations were consistent across CVD subtypes.
CONCLUSIONS: MLTCs burden was a stronger determinant of mortality risk than CVD subtype alone. Findings support moving beyond single-disease models towards integrated, MLTC-informed care, and pandemic preparedness.
METHODS: In this population-based cohort study, linked national electronic health records from England were analysed. Adults aged ≥18 years with CVD and a positive COVID-19 test between 31 January 2020 and 31 October 2022 were included. MLTCs burden was defined as the number of additional long-term conditions beyond CVD (0, 1, 2, or ≥3). One-year mortality was assessed using adjusted flexible parametric Royston-Parmar models.
RESULTS: In 1 081 695 individuals with CVD and COVID-19, 89.7% had at least one long-term condition (LTC) and 67.9% had two or more. Increasing MLTC burden showed a dose-response association with mortality. Compared to individuals without additional LTCs, mortality risk was doubled for those with one LTC (adjusted hazard ratio: 1.86, 95% CI: 1.76-1.96), tripled among those with two LTCs (3.00, 2.85-3.16), and five-fold higher in those with ≥3 LTCs (5.00, 4.75-5.27). Associations were consistent across CVD subtypes.
CONCLUSIONS: MLTCs burden was a stronger determinant of mortality risk than CVD subtype alone. Findings support moving beyond single-disease models towards integrated, MLTC-informed care, and pandemic preparedness.